Literature DB >> 28967504

National Trends and Predictors of Organ-sparing for Invasive Penile Tumors: Expanding the Therapeutic Window.

Juan Chipollini1, Dominic H Tang2, Pranav Sharma3, Philippe E Spiess2.   

Abstract

INTRODUCTION: The purpose of this study was to analyze contemporary trends and predictors in the use of organ-sparing treatment (OST) for low-stage invasive penile tumors as well as to ascertain its impact on overall mortality (OM) in those with high-risk (pT2) disease. PATIENTS AND METHODS: The National Cancer Data Base was queried for patients with clinically nonmetastatic penile cancer and available pathologic tumor (pT) and treatment data from 1998 to 2012. Independent predictors for performance of OST were analyzed. Multivariable Cox proportional hazard regression was used to identify factors of OM in a subset of patients with pT2 disease.
RESULTS: A total of 4231 patients with ≤ pT2cN0cM0 primary penile cancer were identified over a median follow-up of 39.6 months. Approximately 49% of patients received OST over the study period (P = .009). Older age, Hispanic ethnicity, urban counties, academic facilities, and pT2 disease were negative predictors for OST (all P < .05), whereas grade and years of diagnosis where associated with increased performance (P < .01). In subgroup analysis of pT2 patients, older age, black race, comorbidity, node status, and grade were associated with higher OM (all P < .05). When compared with radical penectomy, partial penectomy was associated with decreased OM (hazard ratio, 0.67; 95% confidence interval, 0.52-0.87; P = .002), whereas organ-sparing did not affect survival (hazard ratio, 0.83; 95% confidence interval, 0.52-1.31; P = .419) in these patients.
CONCLUSION: Ethnic and socioeconomic differences exist in the local management of penile tumors. No impact on OM was observed for those with high-risk cases treated with organ-sparing at intermediate follow-up. More studies are needed to evaluate oncologic efficacy of organ-sparing in carefully selected invasive penile tumors.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  High-risk disease; Outcomes; Penile cancer; Penile-sparing; Treatment disparities

Mesh:

Year:  2017        PMID: 28967504     DOI: 10.1016/j.clgc.2017.09.004

Source DB:  PubMed          Journal:  Clin Genitourin Cancer        ISSN: 1558-7673            Impact factor:   2.872


  3 in total

1.  Radical penectomy, a compromise for life: results from the PECAD study.

Authors:  Jamil Ghahhari; Michele Marchioni; Philippe E Spiess; Juan J Chipollini; Peter Nyirády; Judith Varga; Pasquale Ditonno; Stefano Boccasile; Giulia Primiceri; Cosimo De Nunzio; Giorgia Tema; Andrea Tubaro; Alessandro Veccia; Alessandro Antonelli; Gennaro Musi; Ottavio De Cobelli; Andrea Conti; Stefano Puliatti; Salvatore Micali; Mario Álvarez-Maestro; José Quesada Olarte; Erico Diogenes; Marcos Venicio Alves Lima; Andrew Tracey; Georgi Guruli; Riccardo Autorino; Petros Sountoulides; Roman Sosnowski; Luigi Schips; Luca Cindolo
Journal:  Transl Androl Urol       Date:  2020-06

2.  Available active surveillance follow-up protocols for small renal mass: a systematic review.

Authors:  Giacomo Rebez; Nicola Pavan; M Carmen Mir
Journal:  World J Urol       Date:  2021-01-16       Impact factor: 4.226

3.  The prognostic value of lymph node ratio in comparison to positive lymph node count in penile squamous cell carcinoma.

Authors:  Jiajie Yu; Qian Long; Zhiqiang Zhang; Shufen Liao; Fufu Zheng
Journal:  Int Urol Nephrol       Date:  2021-09-28       Impact factor: 2.370

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.